Calcified Alveolar Septal Pulmonary Amyloidosis as an Initial Manifestation of Multiple Myeloma.
Kevorkof GV et al. Arch Bronconeumol. 2018 Mar 5. pii: S0300-2896(18)30020-6. doi: 10.1016/j.arbres.2018.01.005. [Epub ahead of print].

Severe pembrolizumab-associated neutropenia after CD34+ selected allogeneic hematopoietic-cell transplantation for multiple myeloma.
Bryant AR et al. Bone Marrow Transplant. 2018 Mar 7. doi: 10.1038/s41409-018-0142-4. [Epub ahead of print].

Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention.
Lee DH et al. Curr Treat Options Cardiovasc Med. 2018 Mar 6;20(3):19. doi: 10.1007/s11936-018-0618-y.

Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies.
Chen M et al. Ann Hematol. 2018 Mar 2. doi: 10.1007/s00277-018-3284-y. [Epub ahead of print].

Severe abdominal pain and diarrhea – unusual multiple myeloma presentation with a severe prognosis: a case report.
Salguero DA et al. J Med Case Rep. 2018 Mar 18;12(1):70. doi: 10.1186/s13256-018-1598-y.

Bone marrow adiposity and multiple myeloma.
Morris EV et al. Bone. 2018 Mar 13. pii: S8756-3282(18)30118-2. doi: 10.1016/j.bone.2018.03.011. [Epub ahead of print].

Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
Iannaccone A et al. High Blood Press Cardiovasc Prev. 2018 Mar 26. doi: 10.1007/s40292-018-0256-1. [Epub ahead of print].